|
1
|
Pectasides D, Pectasides E, Psyrri A and
Economopoulos T: Treatment issues in clear cell carcinoma of the
ovary: a different entity? Oncologist. 11:1089–1094. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ozols RF, Bundy BN, Greer BE, Fowler JM,
Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM
and Baergen R; Gynecologic Oncology Group. Phase III trial of
carboplatin and paclitaxel compared with cisplatin and paclitaxel
in patients with optimally resected stage III ovarian cancer: a
Gynecologic Oncology Group study. J Clin Oncol. 21:3194–3200. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kajihara H, Yamada Y, Kanayama S, Furukawa
N, Noguchi T, Haruta S, Yoshida S, Sado T, Oi H and Kobayashi H:
Clear cell carcinoma of the ovary: potential pathogenic mechanisms
(Review). Oncol Rep. 23:1193–1203. 2010.PubMed/NCBI
|
|
4
|
Yamaguchi K, Mandai M, Oura T, Matsumura
N, Hamanishi J, Baba T, Matsui S, Murphy SK and Konishi I:
Identification of an ovarian clear cell carcinoma gene signature
that reflects inherent disease biology and the carcinogenic
processes. Oncogene. 29:1741–1752. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mandai M, Matsumura N, Baba T, Yamaguchi
K, Hamanishi J and Konishi I: Ovarian clear cell carcinoma as a
stress-responsive cancer: influence of the microenvironment on the
carcinogenesis and cancer phenotype. Cancer Lett. 310:129–133.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Itamochi H, Kigawa J, Akeshima R, Sato S,
Kamazawa S, Takahashi M, Kanamori Y, Suzuki M, Ohwada M and
Terakawa N: Mechanisms of cisplatin resistance in clear cell
carcinoma of the ovary. Oncology. 62:349–353. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yoshida S, Furukawa N, Haruta S, Tanase Y,
Kanayama S, Noguchi T, Sakata M, Yamada Y, Oi H and Kobayashi H:
Theoretical model of treatment strategies for clear cell carcinoma
of the ovary: focus on perspectives. Cancer Treat Rev. 35:608–615.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Higashiura Y, Kajihara H, Shigetomi H and
Kobayashi H: Identification of multiple pathways involved in the
malignant transformation of endometriosis (Review). Oncol Lett.
4:3–9. 2012.PubMed/NCBI
|
|
9
|
Maeda D and Shih IeM: Pathogenesis and the
role of ARID1A mutation in endometriosis-related ovarian neoplasms.
Adv Anat Pathol. 20:45–52. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Toyokuni S: Mysterious link between iron
overload and CDKN2A/2B. J Clin Biochem Nutr. 48:46–49. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tanase Y, Yamada Y, Shigetomi H, Kajihara
H, Oonogi A, Yoshizawa Y, Furukawa N, Haruta S, Yoshida S, Sado T,
Oi H and Kobayashi H: Modulation of estrogenic action in clear cell
carcinoma of the ovary. Exp Ther Med. 3:18–24. 2012.PubMed/NCBI
|
|
12
|
Kajihara H, Yamada Y, Shigetomi H,
Higashiura Y and Kobayashi H: The dichotomy in the histogenesis of
endometriosis-associated ovarian cancer: clear cell-type versus
endometrioid-type adenocarcinoma. Int J Gynecol Pathol. 31:304–312.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
DeLair D, Oliva E, Köbel M, Macias A,
Gilks CB and Soslow RA: Morphologic spectrum of
immunohistochemically characterized clear cell carcinoma of the
ovary: a study of 155 cases. Am J Surg Pathol. 35:36–44. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hecht JL, Kotsopoulos J, Hankinson SE and
Tworoger SS: Relationship between epidemiologic risk factors and
hormone receptor expression in ovarian cancer: results from the
Nurses’ Health Study. Cancer Epidemiol Biomarkers Prev.
18:1624–3160. 2009.PubMed/NCBI
|
|
15
|
Tsuchiya A, Sakamoto M, Yasuda J, Chuma M,
Ohta T, Ohki M, Yasugi T, Taketani Y and Hirohashi S: Expression
profiling in ovarian clear cell carcinoma: identification of
hepatocyte nuclear factor-1 beta as a molecular marker and a
possible molecular target for therapy of ovarian clear cell
carcinoma. Am J Pathol. 163:2503–2512. 2003. View Article : Google Scholar
|
|
16
|
Uchida H, Maruyama T, Nishikawa-Uchida S,
Oda H, Miyazaki K, Yamasaki A and Yoshimura Y: Studies using an in
vitro model show evidence of involvement of epithelial-mesenchymal
transition of human endometrial epithelial cells in human embryo
implantation. J Biol Chem. 287:4441–4450. 2012. View Article : Google Scholar
|
|
17
|
Wareing M and Greenwood SL: Review:
Potassium channels in the human fetoplacental vasculature.
Placenta. 32:S203–S206. 2011. View Article : Google Scholar
|
|
18
|
Milne SA, Henderson TA, Kelly RW, Saunders
PT, Baird DT and Critchley HO: Leukocyte populations and steroid
receptor expression in human first-trimester decidua; regulation by
antiprogestin and prostaglandin E analog. J Clin Endocrinol Metab.
90:4315–4321. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bulun SE, Cheng YH, Pavone ME, Xue Q,
Attar E, Trukhacheva E, Tokunaga H, Utsunomiya H, Yin P, Luo X, Lin
Z, Imir G, Thung S, Su EJ and Kim JJ: Estrogen receptor-beta,
estrogen receptor-alpha, and progesterone resistance in
endometriosis. Semin Reprod Med. 28:36–43. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Akahane T, Sekizawa A, Okuda T, Kushima M,
Saito H and Okai T: Disappearance of steroid hormone dependency
during malignant transformation of ovarian clear cell cancer. Int J
Gynecol Pathol. 24:369–376. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dhingra N, Punia RS, Radotra A and Mohan
H: Arias-Stella reaction in upper genital tract in pregnant and
non-pregnant women: a study of 120 randomly selected cases. Arch
Gynecol Obstet. 276:47–52. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Trpkov K, Guggisberg K and Yilmaz A:
Arias-Stella reaction as a diagnostic pitfall in a bladder biopsy
with endometriosis: case report and review of the pseudoneoplastic
bladder lesions. Pathol Res Pract. 205:653–656. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sakaki M, Hirokawa M, Sano T, Takahashi H,
Tezuka K, Abe K and Sano M: Ovarian endometriosis showing decidual
change and Arias-Stella reaction with biotin-containing
intranuclear inclusions. Acta Cytol. 47:321–324. 2003.
|
|
24
|
Ohkawa K, Amasaki H, Terashima Y, Aizawa S
and Ishikawa E: Clear cell carcinoma of the ovary: light and
electron microscopic studies. Cancer. 40:3019–3029. 1977.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kato N and Motoyama T: Overexpression of
osteopontin in clear cell carcinoma of the ovary: close association
with HNF-1beta expression. Histopathology. 52:682–688. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Matsuura M, Suzuki T and Saito T:
Osteopontin is a new target molecule for ovarian clear cell
carcinoma therapy. Cancer Sci. 101:1828–1833. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fraga-Silva RA, Costa-Fraga FP, Murça TM,
et al: Angiotensin-converting enzyme 2 activation improves
endothelial function. Hypertension. 61:1233–1238. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Min KW, Park MH, Hong SR, Lee H, Kwon SY,
Hong SH, Joo HJ, Park IA, An HJ, Suh KS, Oh HK, Yoo CW, Kim MJ,
Chang HK, Jun SY, Yoon HK, Chang ED, Kim DW and Kim I; The
Gynecologic Pathology Study Group of the Korean Society of
Pathologists. Clear Cell Carcinomas of the Ovary: A
Multi-Institutional Study of 129 Cases in Korea With Prognostic
Significance of Emi1 and Galectin-3. Int J Gynecol Pathol. 32:3–14.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Oishi T, Itamochi H, Kigawa J, Kanamori Y,
Shimada M, Takahashi M, Shimogai R, Kawaguchi W, Sato S and
Terakawa N: Galectin-3 may contribute to Cisplatin resistance in
clear cell carcinoma of the ovary. Int J Gynecol Cancer.
17:1040–1046. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
von Wolff M, Wang X, Gabius HJ and
Strowitzki T: Galectin fingerprinting in human endometrium and
decidua during the menstrual cycle and in early gestation. Mol Hum
Reprod. 11:189–194. 2005.PubMed/NCBI
|
|
31
|
Noël JC, Chapron C, Borghese B, Fayt I and
Anaf V: Galectin-3 is overexpressed in various forms of
endometriosis. Appl Immunohistochem Mol Morphol. 19:253–257.
2011.PubMed/NCBI
|
|
32
|
Maeda D, Ota S, Takazawa Y, Aburatani H,
Nakagawa S, Yano T, Taketani Y, Kodama T and Fukayama M: Glypican-3
expression in clear cell adenocarcinoma of the ovary. Mod Pathol.
22:824–832. 2009.PubMed/NCBI
|
|
33
|
Tamada Y, Takeuchi H, Suzuki N, Susumu N,
Aoki D and Irimura T: Biological and therapeutic significance of
MUC1 with sialoglycans in clear cell adenocarcinoma of the ovary.
Cancer Sci. 98:1586–1591. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vlad AM, Diaconu I and Gantt KR: MUC1 in
endometriosis and ovarian cancer. Immunol Res. 36:229–236. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Carson DD, Julian J, Lessey BA, Prakobphol
A and Fisher SJ: MUC1 is a scaffold for selectin ligands in the
human uterus. Front Biosci. 11:2903–2908. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kim A, Enomoto T, Serada S, Ueda Y,
Takahashi T, Ripley B, Miyatake T, Fujita M, Lee CM, Morimoto K,
Fujimoto M, Kimura T and Naka T: Enhanced expression of Annexin A4
in clear cell carcinoma of the ovary and its association with
chemoresistance to carboplatin. Int J Cancer. 125:2316–2322. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ponnampalam AP and Rogers PA: Cyclic
changes and hormonal regulation of annexin IV mRNA and protein in
human endometrium. Mol Hum Reprod. 12:661–669. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jiang YL, Li B, Xing FQ, Wang F and Feng
JH: Study on the relationship between altered expression of annexin
A4 and endometrial receptivity during the implantation window in
infertile patients with endometriosis. Zhonghua Fu Chan Ke Za Zhi.
47:324–327. 2012.(In Chinese).
|
|
39
|
Sugita S, Morishita Y, Kano J, Furuya S,
Shiba-Ishii A and Noguchi M: IGFBP-1 is expressed specifically in
ovarian clear cell adenocarcinoma. Histopathology. 58:729–738.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tan DS, Iravani M, McCluggage WG, Lambros
MB, Milanezi F, Mackay A, Gourley C, Geyer FC, Vatcheva R, Millar
J, Thomas K, Natrajan R, Savage K, Fenwick K, Williams A, Jameson
C, El-Bahrawy M, Gore ME, Gabra H, Kaye SB, Ashworth A and
Reis-Filho JS: Genomic analysis reveals the molecular heterogeneity
of ovarian clear cell carcinomas. Clin Cancer Res. 17:1521–1534.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Howell NR, Zheng W, Cheng L, Tornos C,
Kane P, Pearl M, Chalas E and Liang SX: Carcinomas of ovary and
lung with clear cell features: can immunohistochemistry help in
differential diagnosis? Int J Gynecol Pathol. 26:134–140. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pacchiarotti A, Caserta D, Sbracia M and
Moscarini M: Expression of oct-4 and c-kit antigens in
endometriosis. Fertil Steril. 95:1171–1173. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ghosh D and Sengupta J: Endocrine and
paracrine correlates of endometrial receptivity to blastocyst
implantation in the human. Indian J Physiol Pharmacol. 48:6–30.
2004.PubMed/NCBI
|
|
44
|
Li B, Jin H, Yu Y, Gu C, Zhou X, Zhao N
and Feng Y: HOXA10 is overexpressed in human ovarian clear cell
adenocarcinoma and correlates with poor survival. Int J Gynecol
Cancer. 19:1347–1352. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zanatta A, Rocha AM, Carvalho FM, Pereira
RM, Taylor HS, Motta EL, Baracat EC and Serafini PC: The role of
the Hoxa10/HOXA10 gene in the etiology of endometriosis and its
related infertility: a review. J Assist Reprod Genet. 27:701–710.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kobayashi H, Yamada Y, Kanayama S,
Furukawa N, Noguchi T, Haruta S, Yoshida S, Sakata M, Sado T and Oi
H: The role of hepatocyte nuclear factor-1beta in the pathogenesis
of clear cell carcinoma of the ovary. Int J Gynecol Cancer.
19:471–479. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Salameh W, Helliwell JP, Han G, McPhaul L
and Khorram O: Expression of endometrial glycogen synthase
kinase-3beta protein throughout the menstrual cycle and its
regulation by progesterone. Mol Hum Reprod. 12:543–549. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
von Wolff M, Ursel S, Hahn U, Steldinger R
and Strowitzki T: Glucose transporter proteins (GLUT) in human
endometrium: expression, regulation, and function throughout the
menstrual cycle and in early pregnancy. J Clin Endocrinol Metab.
88:3885–3892. 2003.PubMed/NCBI
|
|
49
|
Senkel S, Lucas B, Klein-Hitpass L and
Ryffel GU: Identification of target genes of the transcription
factor HNF1beta and HNF1alpha in a human embryonic kidney cell
line. Biochim Biophys Acta. 1731:179–190. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Xu JM, Wang Y, Ge FJ, Lin L, Liu ZY and
Sharma MR: Severe irinotecan-induced toxicity in a patient with
UGT1A1*28 and UGT1A1*6 polymorphisms. World J Gastroenterol.
19:3899–3903. 2013.PubMed/NCBI
|
|
51
|
Tang SW, Yang TC, Lin WC, Chang WH, Wang
CC, Lai MK and Lin JY: Nicotinamide N-methyltransferase induces
cellular invasion through activating matrix metalloproteinase-2
expression in clear cell renal cell carcinoma cells.
Carcinogenesis. 32:138–145. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Salleh N, Baines DL, Naftalin RJ and
Milligan SR: The hormonal control of uterine luminal fluid
secretion and absorption. J Membr Biol. 206:17–28. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kerschner JL and Harris A: Transcriptional
networks driving enhancer function in the CFTR gene. Biochem J.
446:203–212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ferrè S, Veenstra GJ, Bouwmeester R,
Hoenderop JG and Bindels RJ: HNF-1B specifically regulates the
transcription of the γa-subunit of the Na+/K+-ATPase. Biochem
Biophys Res Commun. 404:284–290. 2011.
|
|
55
|
Kobayashi H, Kajiwara H, Kanayama S,
Yamada Y, Furukawa N, Noguchi T, Haruta S, Yoshida S, Sakata M,
Sado T and Oi H: Molecular pathogenesis of endometriosis-associated
clear cell carcinoma of the ovary (Review). Oncol Rep. 22:233–240.
2009.PubMed/NCBI
|
|
56
|
Gütgemann I, Lehman NL, Jackson PK and
Longacre TA: Emi1 protein accumulation implicates misregulation of
the anaphase promoting complex/cyclosome pathway in ovarian clear
cell carcinoma. Mod Pathol. 21:445–454. 2008.PubMed/NCBI
|
|
57
|
Kuo KT, Mao TL, Chen X, Feng Y, Nakayama
K, Wang Y, Glas R, Ma MJ, Kurman RJ, Shih IeM and Wang TL: DNA copy
numbers profiles in affinity-purified ovarian clear cell carcinoma.
Clin Cancer Res. 16:1997–2008. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ju W, Yoo BC, Kim IJ, Kim JW, Kim SC and
Lee HP: Identification of genes with differential expression in
chemoresistant epithelial ovarian cancer using high-density
oligonucleotide microarrays. Oncol Res. 18:47–56. 2009. View Article : Google Scholar
|
|
59
|
Ozdemir F, Altinisik J, Karateke A,
Coksuer H and Buyru N: Methylation of tumor suppressor genes in
ovarian cancer. Exp Ther Med. 4:1092–1096. 2012.PubMed/NCBI
|
|
60
|
Ho CM, Lai HC, Huang SH, Chien TY, Lin MC
and Chang SF: Promoter methylation of sFRP5 in patients with
ovarian clear cell adenocarcinoma. Eur J Clin Invest. 40:310–318.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Akatsuka S, Yamashita Y, Ohara H, Liu YT,
Izumiya M, Abe K, Ochiai M, Jiang L, Nagai H, Okazaki Y, Murakami
H, Sekido Y, Arai E, Kanai Y, Hino O, Takahashi T, Nakagama H and
Toyokuni S: Fenton reaction induced cancer in wild type rats
recapitulates genomic alterations observed in human cancer. PLoS
One. 7:e434032012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Choi YL, Kang SY, Shin YK, Choi JS, Kim
SH, Lee SJ, Bae DS and Ahn G: Aberrant hypermethylation of RASSF1A
promoter in ovarian borderline tumors and carcinomas. Virchows
Arch. 448:331–336. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Vestergaard AL, Thorup K, Knudsen UB, Munk
T, Rosbach H, Poulsen JB, Guldberg P and Martensen PM: Oncogenic
events associated with endometrial and ovarian cancers are rare in
endometriosis. Mol Hum Reprod. 17:758–761. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Zannoni GF, Morassi F, Prisco MG, De
Stefano I, Vellone VG, Arena V, Scambia G and Gallo D:
Clinicopathologic and immunohistochemical features of ovarian clear
cell carcinomas in comparison with type I and type II tumors. Int J
Gynecol Pathol. 31:507–516. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Eltabbakh GH, Mount SL, Beatty B,
Simmons-Arnold L and Cooper K: Clinical and molecular differences
between clear cell and papillary serous ovarian carcinoma. J Surg
Oncol. 93:379–386. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Axiotis CA, Guarch R, Merino MJ, Laporte N
and Neumann RD: P-glycoprotein expression is increased in human
secretory and gestational endometrium. Lab Invest. 65:577–581.
1991.PubMed/NCBI
|
|
67
|
Nomura H, Tamada Y, Miyagi T, Suzuki A,
Taira M, Suzuki N, Susumu N, Irimura T and Aoki D: Expression of
NEU3 (plasma membrane-associated sialidase) in clear cell
adenocarcinoma of the ovary: its relationship with T factor of pTNM
classification. Oncol Res. 16:289–297. 2006.PubMed/NCBI
|
|
68
|
Liu P, Khurana A, Rattan R, He X, Kalloger
S, Dowdy S, Gilks B and Shridhar V: Regulation of HSulf-1
expression by variant hepatic nuclear factor 1 in ovarian cancer.
Cancer Res. 69:4843–4850. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Collins Y, Dicioccio R, Keitz B, Lele S
and Odunsi K: Methylation of death-associated protein kinase in
ovarian carcinomas. Int J Gynecol Cancer. 16:195–199. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Song H, Kwan SY, Izaguirre DI, Zu Z, Tsang
YT, Tung CS, King ER, Mok SC, Gershenson DM and Wong KK: PAX2
Expression in Ovarian Cancer. Int J Mol Sci. 14:6090–6105. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Cai KQ, Caslini C, Capo-chichi CD, Slater
C, Smith ER, Wu H, Klein-Szanto AJ, Godwin AK and Xu XX: Loss of
GATA4 and GATA6 expression specifies ovarian cancer histological
subtypes and precedes neoplastic transformation of ovarian surface
epithelia. PLoS One. 4:e64542009. View Article : Google Scholar
|
|
72
|
Blanco D, Vicent S, Fraga MF,
Fernandez-Garcia I, Freire J, Lujambio A, Esteller M,
Ortiz-de-Solorzano C, Pio R, Lecanda F and Montuenga LM: Molecular
analysis of a multistep lung cancer model induced by chronic
inflammation reveals epigenetic regulation of p16 and activation of
the DNA damage response pathway. Neoplasia. 9:840–852. 2007.
View Article : Google Scholar
|
|
73
|
McKie AB, Vaughan S, Zanini E, Okon IS,
Louis L, de Sousa C, Greene MI, Wang Q, Agarwal R, Shaposhnikov D,
Wong JL, Gungor H, Janczar S, El-Bahrawy M, Lam EW, Chayen NE and
Gabra H: The OPCML tumor suppressor functions as a cell surface
repressor-adaptor, negatively regulating receptor tyrosine kinases
in epithelial ovarian cancer. Cancer Discov. 2:156–171. 2012.
View Article : Google Scholar
|
|
74
|
Ren F, Wang D, Jiang Y and Ren F:
Epigenetic inactivation of hMLH1 in the malignant transformation of
ovarian endometriosis. Arch Gynecol Obstet. 285:215–221. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Coffinier C, Thepot D, Babinet C, Yaniv M
and Barra J: Essential role for the homeoprotein vHNF1/HNF1beta in
visceral endoderm differentiation. Development. 126:4785–4794.
1999.PubMed/NCBI
|
|
76
|
Horikawa Y, Iwasaki N, Hara M, Furuta H,
Hinokio Y, Cockburn BN, Lindner T, Yamagata K, Ogata M, Tomonaga O,
Kuroki H, Kasahara T, Iwamoto Y and Bell GI: Mutation in hepatocyte
nuclear factor-1β gene (TCF2) associated with MODY. Nat Genet.
17:384–385. 1997.
|
|
77
|
Ogata K, Shimamura Y, Hamada K, Hisa M,
Bun M, Okada N, Inoue K, Taniguchi Y, Ishihara M, Kagawa T, Horino
T, Fujimoto S and Terada Y: Upregulation of HNF-1β during
experimental acute kidney injury plays a crucial role in renal
tubule regeneration. Am J Physiol Renal Physiol. 303:F689–F699.
2012.
|
|
78
|
D’Angelo A, Bluteau O, Garcia-Gonzalez MA,
Gresh L, Doyen A, Garbay S, Robine S and Pontoglio M: Hepatocyte
nuclear factor 1alpha and beta control terminal differentiation and
cell fate commitment in the gut epithelium. Development.
137:1573–1582. 2010.PubMed/NCBI
|
|
79
|
Avni FE and Hall M: Renal cystic diseases
in children: new concepts. Pediatr Radiol. 40:939–946. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Zhou XH, Hui ZY and Li Y: Clinical and
pathological features of a neonate with autosomal recessive
polycystic kidney disease caused by a nonsense PKHD1 mutation.
World J Pediatr. 9:76–79. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Serafini-Cessi F, Monti A and Cavallone D:
N-Glycans carried by Tamm-Horsfall glycoprotein have a crucial role
in the defense against urinary tract diseases. Glycoconj J.
22:383–394. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Sutherland KD, Lindeman GJ, Choong DY,
Wittlin S, Brentzell L, Phillips W, Campbell IG and Visvader JE:
Differential hypermethylation of SOCS genes in ovarian and breast
carcinomas. Oncogene. 23:7726–7733. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Dimitriadis E, Stoikos C, Tan YL and
Salamonsen LA: Interleukin 11 signaling components signal
transducer and activator of transcription 3 (STAT3) and suppressor
of cytokine signaling 3 (SOCS3) regulate human endometrial stromal
cell differentiation. Endocrinol. 147:3809–3817. 2006. View Article : Google Scholar
|
|
84
|
Oktem G, Sanci M, Bilir A, Yildirim Y,
Kececi SD, Ayla S and Inan S: Cancer stem cell and embryonic
development-associated molecules contribute to prognostic
significance in ovarian cancer. Int J Gynecol Cancer. 22:23–29.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Yamada Y, Shigetomi H, Onogi A, Haruta S,
Kawaguchi R, Yoshida S, Furukawa N, Nagai A, Tanase Y, Tsunemi T,
Oi H and Kobayashi H: Redox-active iron-induced oxidative stress in
the pathogenesis of clear cell carcinoma of the ovary. Int J
Gynecol Cancer. 21:1200–1207. 2011.PubMed/NCBI
|
|
86
|
Haruta S, Furukawa N, Yoshizawa Y, Tsunemi
T, Nagai A, Kawaguchi R, Tanase Y, Yoshida S and Kobayashi H:
Molecular genetics and epidemiology of epithelial ovarian cancer.
Oncol Rep. 26:1347–1356. 2011.PubMed/NCBI
|
|
87
|
Kato N, Tamura G and Motoyama T:
Hypomethylation of hepatocyte nuclear factor-1beta (HNF-1beta) CpG
island in clear cell carcinoma of the ovary. Virchows Arch.
452:175–180. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Shigetomi H, Higashiura Y, Kajihara H and
Kobayashi H: A potential link of oxidative stress and cell cycle
regulation for development of endometriosis. Gynecol Endocrinol.
28:897–902. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Cameron RI, Ashe P, O’Rourke DM, Foster H
and McCluggage WG: A panel of immunohistochemical stains assists in
the distinction between ovarian and renal clear cell carcinoma. Int
J Gynecol Pathol. 22:272–276. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Brinkman JA and El-Ashry D: ER
re-expression and re-sensitization to endocrine therapies in
ER-negative breast cancers. J Mammary Gland Biol Neoplasia.
14:67–78. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Iida Y, Aoki K, Asakura T, Ueda K,
Yanaihara N, Takakura S, Yamada K, Okamoto A, Tanaka T and Ohkawa
K: Hypoxia promotes glycogen synthesis and accumulation in human
ovarian clear cell carcinoma. Int J Oncol. 40:2122–2130.
2012.PubMed/NCBI
|
